The Medical Minute: What is myelodysplastic syndrome?

June 15, 2012 By Dr. David Claxton

Television journalist and host of "Good Morning America" Robin Roberts announced this week that she has myelodysplastic syndrome, or MDS, an uncommon blood and bone marrow disorder.

MDS is a involving the cells that make up our -- , , and platelets. It is typically a slow-growing type of cancer that affects older people, but it can occur in younger adults and even children.

Certain types of chemotherapy predispose people to MDS, including some common treatments for types of , , and some gastrointestinal malignancies. But many cases of MDS are also found in people who have not been exposed to chemotherapy, so we don’t understand clearly what causes the process.

MDS used to be referred to as “pre-leukemia,” a term doctors don’t use much anymore because although many MDS cases will turn into leukemia, many will not. In some patients with a diagnosis of MDS, the disorder turns into leukemia within just a few months, whereas with others, the condition may remain stable over many years.

Watch Dr. Claxton talk more about MDS

There also are a group of disorders that doctors refer to as myeloproliferative disorders, or myeloproliferative syndromes, which has some overlap with MDS. These are different in that the process is more proliferative, seen as increased bone marrow cells in the blood and growth of the spleen. In MDS, however, the blood are usually reduced and, in most cases, the spleen is normal in size.

Symptoms of MDS include weakness, or bleeding or bruising, but there are many other conditions that can also cause those same symptoms. MDS is usually diagnosed after a doctor requests blood work from a patient and blood cell counts -- red cell counts, white cell counts, or platelet counts -- are found to be abnormally low.

In most MDS patients the initial problem is low blood cell counts, specifically red cell counts. Many patients need transfusions over a number of years. Medications also can be effective for some MDS patients. There are two injectable chemotherapies that can sometimes produce complete remission of MDS and, in other cases, offer significant benefit over time. For a selective small group of MDS patients, an oral medication can be very effective. There also are a number of investigational research treatments as part of an active field of study to find a treatment and cure. Today, the only cure for MDS is bone marrow and stem cell transplantation from another individual; for younger patients with MDS this is a particularly good option.

For any given patient with MDS, doctors will examine various factors to determine prognosis. For example, if the changes in the bone marrow suggest a more proliferative or malignant state, that implies increased risk over time for develop of leukemia and death or complications. Chromosome studies are important for understanding risk in MDS, so the bone marrow is examined for changes in chromosomes. MDS patients who develop the disease after are generally at greater risk for problems over time.

In older individuals, MDS and its treatment may affect quality of life but not affect longevity because of other health problems that are more likely to pose a problem before the MDS would become more serious. For younger individuals it is often a serious, life changing and often life-threatening problem.

The limited effective therapies for MDS therefore justify the research efforts underway. Our understanding of MDS is increasing, but better treatments are needed for this difficult problem.

Explore further: Discovery of genetic mutations better diagnose myelodysplastic syndromes

Related Stories

Discovery of genetic mutations better diagnose myelodysplastic syndromes

June 30, 2011
For patients with myelodysplastic syndromes (MDS), choosing the appropriate treatment depends heavily on the prognosis. Those patients at the highest risk of dying from their disease are typically offered the most aggressive ...

Study: Blood cancer may be more common than realized

December 21, 2011
(Medical Xpress) -- A group of life-threatening blood disorders collectively called myelodysplastic syndrome, or MDS, may occur four times more often than reported by national cancer registries, according to new research ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Tom_Hennessy
not rated yet Jun 15, 2012
There is a theory myelodysplasia is a result of increased levels of iron in the body resulting from our high dietary iron , which causes increased red blood cell production. This increased red cell production leads to leukemia.

"Iron chelation and antioxidant therapy may be suitable for the management of MDS".

"Iron Chelation Therapy in Myelodysplastic Syndromes"

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.